PolandPoland

Actavis and Bioton set out to conquer diabetes market

31.01.2012

Zug/Warsaw - The fourth largest generics producer and a polish biotech want to create a stir in the market for diabetes drugs. Swiss Actavis and Bioton from Warsaw announced that they have formed a joint venture company for the development and registration of insulins, including analogue insulins. Bioton will do all the heavy lifting, means developing and manufacturing the insulin products, while Actavis, which has roots in Iceland, will sell them more or less all over the world. Only in Bioton's backwater Poland, will each company will offer the insulin under their respective brands. Actavis will invest €55m, of which €22.5m was splashed out at the signing of the contract on Monday. Actavis' CEO Claudio Albrecht sees great potential in the world market for insulin drugs, which amasses revenues of currently €12b and is expected to grow in double digits over the next years. "We hope to be the first to launch a biosimilar insulin", Albrecht told Reuters, a news agency. Actavis has plans beyond insulin, though. He announced to launch a biosimilar for bestselling drugs every month during the first eight months of 2012.

PolandPoland

21.02.2009

Kraków – According to a report from Kraków-based PMR Ltd, the Czech Republic and Poland are on top in eastern Europe when it comes to outsourcing clinical trials and contract manufacture. The market analysis outlines 160...

PolandPoland

21.02.2009

Szczecin – The West-Pomeranian Center for Advanced Technologies and the German regional cluster BioCon Valley are setting up a German-Polish contact point for the life sciences. The long-term goal of the cooperation, which will...

PolandPoland

21.02.2009

Raszyn Rybie – Polish Euroimplant S.A. has received a66,000 in funding from the National Center for Research and Development (NCBiR) for product development, according to CE.biotech.com. The specialist firm for tissue...

PolandPoland

21.02.2009

Warsaw – Polish insulin and antibiotics maker Bioton S.A. has shuffled its mana­gement board after announcing that an expected deal failed to materialise. In mid-January, after Prokom Investments (Gdynia) proved unable to sell...

PolandPoland

21.02.2009

Kraków – BioCentrum Sp. zo.o. is expanding contract research activities for the bio-pharmaceutical industry. In December, the Polish specialist for preclinical ADME, cell-based assays, protein characterisation, antibody, enzyme...

PolandPoland

23.01.2009

Warsaw – Polish insulin and antibiotics maker Bioton S.A. has shuffled its management board after a failed deal hit the news. When Prokom Investments (Gdynia) failed to sell a 33.3% stake in Bioton to Jerzy Starak’s Polpharma for...

PolandPoland

11.11.2008

Warsaw – In August, the lower chamber of the Polish parliament approved a 31m EUR programme for the protection of mental health to run from 2009-2013. The programme, which is to be financed from the state budget and EU funds,...

PolandPoland

18.08.2008

Portoroz – Around 120 international bioprocessing experts met at the 3rd Monolith Summer Symposium at Portoroz to discuss how monolith chromatography can eliminate current bottlenecks in downstream processing of biological drugs....

PolandPoland

20.05.2008

Krakow – Selvita Sp. z o.o., a newly founded service provider to the biotechnological and pharmaceutical industries, has taken over biotech tools and services supplier BioCentrum Ltd. At the end of March, Selvita acquired 64% of...

PolandPoland

20.05.2008

Warsaw – Together with the top ten Polish universities, one hundred Polish technology companies have kicked-off a business chamber for advanced technology (PIGZT). The chamber will provide a platform for improving information...

Displaying results 31 to 40 out of 108

< Previous 31-40 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-poland/browse/3/article/actavis-and-bioton-set-out-to-conquer-diabetes-market.html

Events

All Events

Stock list

All quotes

TOP

  • CO.DON3.13 EUR5.03%
  • 4SC1.06 EUR3.92%
  • SANTHERA88.65 CHF2.78%

FLOP

  • CYTOS0.19 CHF-9.52%
  • WILEX2.13 EUR-6.99%
  • FORMYCON8.03 EUR-5.42%

TOP

  • PAION3.18 EUR30.9%
  • CO.DON3.13 EUR26.2%
  • FORMYCON8.03 EUR17.7%

FLOP

  • CYTOS0.19 CHF-24.0%
  • ADDEX3.13 CHF-21.4%
  • EVOTEC3.06 EUR-18.2%

TOP

  • SANTHERA88.65 CHF2088.9%
  • PAION3.18 EUR238.3%
  • CO.DON3.13 EUR229.5%

FLOP

  • CYTOS0.19 CHF-95.1%
  • 4SC1.06 EUR-45.4%
  • THERAMETRICS0.08 CHF-42.9%

No liability assumed, Date: 29.09.2014


Current issue

All issues

Product of the week

Products